Enbrel etanercept: Phase II data; marketed to treat rheumatoid arthritis and psoriatic arthritis

Results of a Phase II trial in 112 patients with moderate to severe plaque psoriasis showed that 30% of Enbrel patients achieved a 75% improvement in PASI (PASI 75) score after 3 months compared to 2%...